Physician profile
Celinde Y Strohl
NPI 1912990409
$14,241.14
in general payments reported to CMS, 2019-2025
78 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,940 · 2020: $1,739 · 2021: $2,471 · 2022: $2,319 · 2023: $2,107 · 2024: $2,259 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,771.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,832.96 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $1,588.97 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,076.68 | 2019-2025 | Breztri, Lokelma, Airsupra |
| Novo Nordisk INC | $1,013.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $987.72 | 2019-2025 | |
| Allergan, INC. | $617.76 | 2019-2021 | |
| Lilly USA, LLC | $561.53 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novartis Pharmaceuticals Corporation | $428.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $418.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $403.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $400.84 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $320.15 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $313.42 | 2020-2025 | Nexletol |
| Eisai INC. | $306.78 | 2020-2021 | |
| Amarin Pharma, INC. | $291.34 | 2019-2021 |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celinde Strohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.